Fundraising Fox
NeuroDex
Arlington, US · Founded 2018 · 16 employees on LinkedIn · 3 known investors
Find your way into NeuroDex
115 people in our graph share verified history with the NeuroDex team — schools, employers, funds. One of them is your warm intro.
NeuroDex develops blood-based biomarkers and diagnostic assays for neurological diseases, including rare genetic disorders, Parkinson's disease, Alzheimer's disease, and ALS. The company works with biopharmaceutical companies to enable patient selection, treatment monitoring, and accelerated disease diagnosis in clinical development programs.
Founders & leadership
NeuroDex was founded in 2018 by Erez Eitan.
Investors · 3
How we know: Formation Venture Engineering's portfolio page · Not right? Tell us
How we know: open dataset · investor-profiles · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$1.4M disclosed across 3 rounds · 2020–2023
▶$60KraisedMay 2023 · 1 investors · BiotechnologyRule 506(b)
- Gary MagnantDirector
- Oded BiranExecutive Officer, Director
- Raphael NirDirector
- Erez EitanExecutive Officer, Director
- Offering amount
- $750K
- Amount sold
- $60K
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$800KraisedAug 2022 · 3 investors · BiotechnologyRule 506(b)
- Erez EitanExecutive Officer, Director
- Gary MagnantDirector
- Raphael NirDirector
- Oded BiranExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $800K
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$500KraisedFeb 2020 · 1 investors · BiotechnologyRule 506(b)
- Raphael NirDirector
- Oded BiranExecutive Officer, Director
- Erez EitanExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $500K
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does NeuroDex do?
- NeuroDex develops blood-based biomarkers and diagnostic assays for neurological diseases, including rare genetic disorders, Parkinson's disease, Alzheimer's disease, and ALS. The company works with biopharmaceutical companies to enable patient selection, treatment monitoring, and accelerated disease diagnosis in clinical development programs.
- Who founded NeuroDex?
- NeuroDex was founded by Erez Eitan in 2018.
- Who are NeuroDex's investors?
- NeuroDex's investors include Formation Venture Engineering, ICV, ICV Venture Engineering.
- How much funding has NeuroDex raised?
- NeuroDex has disclosed $1.4M raised across 3 rounds.
- Where is NeuroDex headquartered?
- NeuroDex is headquartered in Arlington, US.